Posted by Michael Wonder on 20 Aug 2021
Astellas receives European Commission approval for first in class Evrenzo (roxadustat) for adult patients with symptomatic anaemia of chronic kidney disease
20 August 2021 - Roxadustat is the first orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor available for adult patients with anaemia associated with chronic kidney disease in Europe.
Astellas Pharma and FibroGen today announced that the European Commission has approved Evrenzo (roxadustat) for the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease.
